Insider Transactions in Q2 2023 at Crinetics Pharmaceuticals, Inc. (CRNX)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 20
2023
|
Marc Wilson CFO |
SELL
Open market or private sale
|
Direct |
30,922
-13.83%
|
$587,518
$19.96 P/Share
|
|
Jun 20
2023
|
Marc Wilson CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+14.8%
|
$180,000
$9.28 P/Share
|
|
Jun 16
2023
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Indirect |
50,000
-6.84%
|
$1,000,000
$20.81 P/Share
|
|
Jun 16
2023
|
Camille L Bedrosian |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+50.0%
|
-
|
|
Jun 16
2023
|
Matthew K Fust |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+24.45%
|
-
|
|
Jun 16
2023
|
Weston Nichols |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+50.0%
|
-
|
|
Jun 16
2023
|
Stephanie Okey |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+50.0%
|
-
|
|
Jun 16
2023
|
Wendall Wierenga |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+5.36%
|
-
|
|
Jun 16
2023
|
Caren Deardorf |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+50.0%
|
-
|
|
Jun 16
2023
|
Coelho Rogerio Vivaldi |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+35.29%
|
-
|
|
Jun 08
2023
|
Coelho Rogerio Vivaldi |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$110,000
$22.06 P/Share
|
|
Apr 05
2023
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
8,212
-64.6%
|
$131,392
$16.15 P/Share
|
|
Apr 03
2023
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,288
-25.22%
|
$64,320
$15.98 P/Share
|